Literature DB >> 3965109

The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis.

J B Miller, J R Testa, V Lindgren, J D Rowley.   

Abstract

Six of eight (75%) patients with postpolycythemic myelofibrosis (PPMF) and 11 of 20 (55%) patients with idiopathic myelofibrosis (MF), seen at the University of Chicago, had abnormal karyotypes in cells of bone marrow origin. The specific chromosomal findings and their clinical significance in these patients were analyzed. A review of the literature added the findings from abnormal karyotype studies in 10 patients with PPMF and 36 patients with MF to this series. The demonstration of an increased frequency of cytogenetic abnormalities after cytotoxic therapy in polycythemia vera (PV) implies that such therapy may have a role in the development of chromosomal changes seen in treated PV and PPMF. The cytogenetic abnormalities in MF appear to be unrelated to therapy except possibly for an association with partial or complete losses of chromosome 5 or 7. Trisomy 8 is the only finding that is more common in MF than in PPMF. Other abnormalities were more common in PPMF, particularly 20q-, loss of 7 or 7q-, and trisomy 9, and to a lesser extent trisomy 1q and 5q-. Cytogenetic abnormalities do not show a pattern that can be used to distinguish between PPMF and MF, nor are they useful in the prognosis of MF or in initial studies in PPMF. PPMF does appear to have a higher tendency toward leukemic transformation than does MF, and an evolution in karyotype appears to have serious prognostic implications in PPMF in regard to this transition.

Entities:  

Mesh:

Year:  1985        PMID: 3965109     DOI: 10.1002/1097-0142(19850201)55:3<582::aid-cncr2820550318>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

Review 1.  The map of chromosome 20.

Authors:  N E Simpson
Journal:  J Med Genet       Date:  1988-12       Impact factor: 6.318

2.  Polycythemia vera. A clinical study of 141 patients.

Authors:  B Anger; U Haug; R Seidler; H Heimpel
Journal:  Blut       Date:  1989-12

3.  Cytogenetics of chronic myelogenous leukemia (CML) correlated to the histopathology of bone marrow biopsies.

Authors:  M Werner; V Kaloutsi; T Buhr; S Delventhal; K F Vykoupil; A Georgii
Journal:  Ann Hematol       Date:  1991-10       Impact factor: 3.673

4.  Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis.

Authors:  Moo-Kon Song; Joo-Seop Chung; Sung-Nam Lim; Gyeong-Won Lee; Sang-Min Lee; Nam-Kyung Lee; Jae-Cheol Choi; So-Yeon Oh
Journal:  Int J Hematol       Date:  2016-06-27       Impact factor: 2.490

5.  Factors affecting prognosis in myelofibrosis.

Authors:  Francesco Onida
Journal:  F1000 Med Rep       Date:  2009-07-08

6.  Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.

Authors:  Ayalew Tefferi; Maura Nicolosi; Mythri Mudireddy; Terra L Lasho; Naseema Gangat; Kebede H Begna; Curtis A Hanson; Rhett P Ketterling; Animesh Pardanani
Journal:  Leukemia       Date:  2018-02-02       Impact factor: 11.528

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.